Read the News and Earn Credit - Click for Credit

For news and views that matter to dermatology
Click here »

Video Highlights of Skin Disease Education Foundation's 11th Annual Psoriasis Forum


Bookmark and Share
04/15/16

Activity Information

 

Release Date: April 2016
Expiration Date: April 30, 2017
Estimated Time to Complete Activity: 1.75 hours

Jointly provided by:

Supported by educational grants from:

  • AbbVie Inc.
  • Amgen Inc.
  • Celgene Corporation
  • Novartis Pharmaceuticals Corporation

 

Access to accompaning print supplements can be found here:

Read Supplement to Seminars in Cutaneous Medicine and Surgery
Supplement to Dermatology News

Method of Participation

Participants should review the activity information, watch the videos in their entirety and complete the online post-test and evaluation. Upon successful completion of the online test and evaluation form, you will be directed to a webpage that will allow you to print your certificate of credit.

Target Audience

This educational activity has been designed for dermatologists, family physicians, physician assistants, nurses, nurse practitioners, and other clinicians who treat patients with psoriasis.

Statement of Need

The estimated 7 million Americans with psoriasis and their clinicians can now choose from an expanded—and soon to be even longer—list of effective and safe medications to treat their disease. This is especially true of systemic therapies used to treat patients with moderate to severe disease. The approval of several tumor necrosis factor (TNF) inhibitors for psoriasis was followed by the availability of biologic agents and small molecules that target other pathogenetic pathways. Additional agents having a variety of mechanisms of action currently are being investigated in phase III clinical trials.

To ensure the optimum management of each patient, clinicians must remain up-to-date on ongoing research involving both currently available and emerging treatments. Clinicians will benefit from this educational activity, which provides an update regarding the effective and safe use of the systemic agents now available as well as the emerging therapies that show promise. The videos focus on appropriate patient selection for various therapies, recommendations for monitoring patients during treatment, and emerging therapies that may become available in the near future.

Learning Objectives

After completing this activity, participants should be better able to:

  • Assess patients for comorbidities and manage psoriasis as well as associated comorbidities
  • Describe the mechanisms of action, efficacy, and safety of currently available biologics used to treat psoriasis.
  • Review their current practice protocols for screening and monitoring patients with psoriasis who are candidates for or are being treated with biologic agents.

Joint Provider Statements

Physicians
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Rutgers, The State University of New Jersey and Global Academy for Medical Education. Rutgers, The State University of New Jersey is accredited by the ACCME to provide continuing medical education for physicians.

Rutgers, The State University of New Jersey designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Rutgers, The State University of New Jersey, Center for Continuing and Outreach Education (CCOE) is an approved provider of continuing nursing education by the New Jersey State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider Number P173-5/31/16.

This activity is awarded 1.83 contact hours. (60 minute CH)

Nurses should only claim those contact hours actually spent participating inthe activity.

Faculty

 

Francisco A. Kerdel, BSc, MBBS, Chair
Director of Inpatient Dermatology
University of Miami Hospital
Professor of Dermatology and Vice Chairman
Florida International University
Miami, Florida

Kristina Callis Duffin, MD, MS
Assistant Professor, Dermatology
University of Utah
Salt Lake City, Utah

 

Craig L. Leonardi, MD
Clinical Professor of Dermatology
Saint Louis University
Central Dermatology
St Louis, Missouri

 

Disclosure Declarations

In accordance with the disclosure policies of Rutgers and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants:
1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and
2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Faculty Disclosures

Kristina Callis Duffin, MD, MS, Grant/Research: AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Janssen Biotech, Inc., Pfizer Inc. and Stiefel Laboratories, Inc. Consultant: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis Pharmaceuticals Corporation, Pfizer, and XenoPort, Inc. Scientific Advisory Board: Eli Lilly and Janssen.

Francisco A. Kerdel, BSc, MBBS, Grant/Research: AbbVie, Amgen, AstraZeneca, Celgene, Galderma Laboratories, L.P., Janssen, Novartis, Pfizer and Valeant. Advisory Board: Celgene. Speakers Bureau: AbbVie, Amgen, Celgene, Galderma, and Janssen.

Craig L. Leonardi, MD, Grant/Research: AbbVie, Amgen, Celgene, Coherus BioSciences, Dermira Inc., Eli Lilly, Galderma Laboratories, L.P., Janssen, LEO Pharma, Merck, Novartis, Pfizer, Sandoz Inc., Stiefel, and Wyeth. Consultant: AbbVie, Amgen, Dermira, Eli Lilly, Janssen, LEO, Pfizer, Sandoz, and UCB, Inc. Speakers Bureau: AbbVie and Celgene.

Peer Review Statement

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, CCOE has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content, and balance of presentation by: Claudia Carron, MSN, RN, Point of Care Coordinator, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. Ms. Carron has no relevant financial relationships to disclose.

Field Testers: This activity was pilot-tested for time required by: Physicians- Steve Draikwicz, MD, Daniel Grabell, MD, Shreya Patel, MD Nurses- Kathleen Brown, LPN, Geraldine Bocchieri, RN, BSN, Carol Ruland, RN. The field testers have no relevant financial relationships to disclose.

Rutgers, The State University of New Jersey: Tristan Nelsen, MNM, CMP, and Patrick Dwyer have no relevant financial relationships to disclose.

Global Academy for Medical Education Staff: Shirley V. Jones, MBA; Sylvia H. Reitman, MBA, DipEd; and Joanne Still, BA, have no relevant financial relationshipsto disclose.

Off Label/Investigational-Use Disclosure

This activity discusses the following investigational products, not yet approved: brodalumab, guselkumab, ixekizumab, and tildrakizumab. Also discussed is the investigational use in clinical trials of patients with psoriasis of the approved agent, tofacitinib.

This continuing education activity was developed from Skin Disease Education Foundation's 11th Annual Psoriasis Forum, held October 31, 2014, in Las Vegas, NV. The ideas and opinions expressed in this activity are those of the Speakers and do not necessarily reflect the views of the supporters, Global Academy for Medical Education, Rutgers, or the publisher.

Copyright Statement

Copyright © 2016 by Global Academy for Medical Education, LLC, and its Licensors. All rights reserved. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission from the Publisher. Global Academy for Medical Education, LLC will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this activity, including any claims related to the products, drugs, or services mentioned herein. Developed in the United States of America.

Provider Contact Information

Please direct content or CE related questions or concerns to CCOE at 973-972-4267 or email ccoe@ca.rutgers.edu.

Contact Information for Technical Questions

Please technical questions or concerns to Global Academy for Medical Education at 973-290-8225 or email info@globalacademycme.com.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above




 


click me